Roche Holding AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All RHO.DE news ›Alector: Maintaining "Hold" ABC Platform Transition And GCase Partnership With Roche
Alector (ALEC) holds steady despite trial failures, pivoting to ABC platform and Roche deal extending cash to 2029. - Alector maintains a "Hold" rating after major clinical setbacks and GSK partnership termination. - Despite failed…
Roche double halts Bristol fightback as Stormers win 49–12
Reduced to thirteen for a spell, the Stormers beat Bristol 49–12 in Cape Town. Jonathan Roche's second try ended the English side's fightback before a prolific finish. Contribution SNA · Author profile · 18/10/2026 09:57 UTC Synthetic…
I Polled 12 Dermatologists for Their Favorite La Roche-Posay Products—These 5 Came Up Again and Again
One is just $14—and seven derms recommended it. It’s no secret that dermatologists love La Roche-Posay. Products from the famed French brand turn up in nearly every skin care article I write, whether it’s on anti-aging, skinimalism,…
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
The FDA approved Roche's satralizumab (Enspryng), an IL-6 receptor-targeting monoclonal antibody, for adults with thyroid eye disease based on the Phase 3 SatraGO-1 and SatraGO-2 trials, giving patients the first at-home subcutaneous…
Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts
Large pharmaceutical companies including Gilead Sciences, Roche and AstraZeneca spent this week securing access to discovery technologies and experimental candidates that address clear biological gaps, instead of large-scale acquisitions…
Cardinal Roche Rules Out Any Return to Freedom for the Traditional Mass
How far will Rome go to eliminate the traditional Mass? Cardinal Roche's statements leave little doubt about the determination of its opponents. “He will not change Traditionis Custodes. He will not revert to Summorum Pontificum.” For…
FDA clears Roche's Enspryng for thyroid eye disease
Roche has claimed US approval for IL-6 receptor antagonist Enspryng in a second indication – thyroid eye disease (TED) – that furthers its ambition to grow the drug into a blockbuster product. Enspryng (satralizumab) has been approved for…
AMAZING K9 DUOS: Social Work Roche and facility dog Lily
WFSB AMAZING K9 DUOS: Social Work Roche and facility dog Lily Meriden crossing guard struck and killed remembered by family Police investigating after teenager found with serious injuries in West Hartford Teenager badly hurt after being…
Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio
Roche (RHHBY) will present phase III cancer results at ESMO 2026, including divarasib’s superiority over first-generation KRAS G12C inhibitors. The meeting runs from 23 to 27 October in Madrid. Krascendo 1 compared divarasib with sotorasib…
Roche reports phase 3 data on steroid-free therapy for UME management
Next year is gearing up for anticipated regulatory movement in the uveitic macular edema (UME) space. Why, you ask? One word: vamibikart. Following Roche’s latest phase 3 data readout during the American Academy of Ophthalmology (AAO) 2026…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com20
-
tradingview.com7
-
openpr.com6
-
firstwordpharma.com4
-
freedom959.net4
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.